CS Professional · Compliance Management, Audit and Due Diligence · Audit Principles and Techniques
For testing an approval control at Ganga Steels Ltd, the auditor first sets the tolerable rate of deviation at 8%. The auditor then revises it to 4%, keeping all other factors unchanged. According to SA 530, what happens to the sample size?
The sample size increases. SA 530 explains that the lower the tolerable rate of deviation, the larger the sample size must be, so tightening the tolerance from 8% to 4% requires testing more items.
- AIt decreases, because a lower tolerance means less testing
- BIt remains unchanged, as tolerable rate does not affect sample size
- CIt increases, because the lower the tolerable rate of deviation, the larger the sample size needs to beCorrect
- DIt becomes irrelevant, as the sample is replaced by inquiry
Explanation
SA 530 Appendix 2 states that an increase in the tolerable rate of deviation decreases sample size; conversely, the lower the tolerable rate, the larger the sample. Reducing it from 8% to 4% therefore enlarges the sample.
Did you get it right without looking?
One question tells you little. A timed set on Audit Principles and Techniques shows your real accuracy, how long you take and where you lose marks.
More Audit Principles and Techniques questions
- An auditor of Ganga Agro Ltd wants to rely on evidence from last year's audit about the company's land title documents. Under SA 200, when m…
- A junior at Himalaya Cements Ltd's audit firm asks whether the auditor must always state inherent risk and control risk separately in the wo…
- During planning of the audit of Ganga Pharma Ltd, the auditor decides to test a population of 4,000 vendor invoices. Which statement correct…
- The auditor of Himalaya Pharma Ltd finds that the SA requirements, applied as written, do not address an unusual revenue arrangement in a ne…
- When designing tests of controls and tests of details for Ritu Exports Ltd, the auditor asks what SA 500 requires about choosing items for t…
- The management of Narmada Pharma Ltd argues that because the applicable financial reporting framework has no specific rule for a new type of…